Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib

Ogkologos - 31 Ιουλίου, 2025

FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk...

Ogkologos - 31 Ιουλίου, 2025

HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours

Ogkologos - 30 Ιουλίου, 2025

Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with...

Ogkologos - 29 Ιουλίου, 2025

Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy,...

Ogkologos - 28 Ιουλίου, 2025

FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung...

Ogkologos - 25 Ιουλίου, 2025

EMA Recommends Extension of Indications for Tislelizumab

Ogkologos - 24 Ιουλίου, 2025

Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone...

Ogkologos - 23 Ιουλίου, 2025

Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in...

Ogkologos - 22 Ιουλίου, 2025

ESMO Welcomes EU Proposals for MFF & FP10 and Calls for...

Ogkologos - 21 Ιουλίου, 2025

1...434445...440 Σελίδα 44 από 440

MOST POPULAR

EMA Recommends Granting a Marketing Authorisation for Capmatinib

13 Μαΐου, 2022

Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in...

6 Δεκεμβρίου, 2021

Epigenetic Changes Pinpointed as the Cause of Some GISTs

19 Νοεμβρίου, 2019

Insulin Resistance May Contribute to Poorer Breast Cancer Outcomes, Study Says

2 Ιουνίου, 2020

Φόρτωση περισσοτέρων

EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib

FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk...

HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours

Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with...

Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy,...

FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung...

EMA Recommends Extension of Indications for Tislelizumab

Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone...

Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in...

ESMO Welcomes EU Proposals for MFF & FP10 and Calls for...

MOST POPULAR

EMA Recommends Granting a Marketing Authorisation for Capmatinib

Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in...

Epigenetic Changes Pinpointed as the Cause of Some GISTs

Insulin Resistance May Contribute to Poorer Breast Cancer Outcomes, Study Says

HOT NEWS

Young Breast Cancer Survivors Without a Germline Pathogenic Variant Have a...

EMA Recommends Granting a Conditional Marketing Authorisation for Selpercatinib

Cancer target missed for 55,000 patients over 6 years

What Are Drug Shortages and How Can They Impact Care for...

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ